Literature DB >> 20944764

Robert Arthur Kyle, MD: a conversation with the editor.

Robert Arthur Kyle1, William Clifford Roberts.   

Abstract

Year:  2010        PMID： 20944764      PMCID： PMC2943456          DOI： 10.1080/08998280.2010.11928660

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  90 in total

1.  Immunoglobulin free light chains and solitary plasmacytoma of bone.

Authors:  David Dingli; Robert A Kyle; S Vincent Rajkumar; Grzegorz S Nowakowski; Dirk R Larson; John P Bida; Morie A Gertz; Terry M Therneau; L Joseph Melton; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

2.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

Review 3.  The spectrum of IgM monoclonal gammopathy in 430 cases.

Authors:  R A Kyle; J P Garton
Journal:  Mayo Clin Proc       Date:  1987-08       Impact factor: 7.616

4.  Chronic idiopathic neutropenia. A newly recognized entity?

Authors:  R A Kyle; J W Linman
Journal:  N Engl J Med       Date:  1968-11-07       Impact factor: 91.245

5.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

6.  Second malignancies associated with chemotherapeutic agents.

Authors:  R A Kyle
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

7.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

Authors:  R A Kyle; M A Gertz; P R Greipp; T E Witzig; J A Lust; M Q Lacy; T M Therneau
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

8.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

Review 10.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.